Methamphetamine - UCLA Integrated Substance Abuse Programs

More documents

Recommendations

Info

Study I: Epidemiology of Psychiatric IllnessGlasner-Edwards, S., Mooney, L.J., Marinelli-Casey, P., Hillhouse, M., Ang, A., &Rawson, R. (under review). Psychopathology in methamphetamine dependentadults 3 years after treatment.‣ Aims• To characterize prevalence of psychiatric illness in MAdependent adults 3 years post-treatmenttreatment• To examine association of psychiatric illness withtreatment retention and outcomes at 3-year 3follow-up‣ HypothesisPsychiatric diagnoses and severity will be associated withpoorer treatment retention and outcomes.‣ Measures• Mini-International Neuropsychiatric Interview, ASI, BSI
Results: Psychiatric Diagnoses (N=526)Diagnosis Current (%) Life (%)Any Psychiatric Disorder 34.0 34.6Affective DisordersMajor Depression 15.2 ***Major Depression, Recurrent *** 9.1Mania 3.9 8.5Hypomania 2.4 9.3Any Affective Disorder 22.2 24.5Any Anxiety Disorder 23.4 ***Psychotic Disorders 4.9 12.7Antisocial Personality Disorder *** 25.8
Page 1: Methamphetamine: Modifications in B
Page 10: Respiratory Disorders and MA Use‣
Page 13: In other words:A Major Reason Peopl
Page 22 and 23: Meth
Page 24 and 25: dopaminereservoirsynapse
Page 26 and 27: Prolonged Drug Use ChangesThe Brain
Page 28 and 29: Effects of Drugs on Dopamine Releas
Page 30 and 31: Control> MA43210
Page 32 and 33: Labeling of EmotionBrain scans were
Page 34 and 35: How muchdoes the brain heal?
Page 36 and 37: Partial Recovery of Brain DopamineT
Page 38 and 39: Methamphetamine Use, Self-Reported
Page 40 and 41: Neural Activation Patterns ofMetham
Page 42 and 43: Results Continued‣ 9 areas within
Page 44 and 45: Implications of Results• Neural a
Page 46 and 47: Acute MA Psychosis‣ Extreme Paran
Page 48 and 49: MA Psychosis Inpatients from 4 Coun
Page 50 and 51: MAT-SS Psychiatric andMedical Studi
Page 54 and 55: Association of Diagnoses with Outco
Page 56 and 57: Results: Major Depressive DisorderR
Page 58 and 59: ‣ HypothesesStudy III: Psychotic
Page 60 and 61: ‣ AimStudy IV: Risk Factors for D
Page 62 and 63: ‣ AimStudy V: Risk Factors for Su
Page 64 and 65: Study VI: Medical Illness in MA Use
Page 66 and 67: Prenatal Meth. Exposure‣ Prelimin
Page 68 and 69: My Sexual Pleasure isEnhanced by th
Page 70 and 71: Behavior Symptom Inventory(BSI) Sco
Page 72 and 73: Hepatitis C by Route50454440% Preve
Page 74 and 75: Clinical Challenges with Methamphet
Page 76 and 77: Why the “MA treatment doesn’two
Page 78 and 79: StatisticsAnalysis of:‣ Drop out
Page 81 and 82: MA Treatment Issues‣ Acute MA Ove
Page 83 and 84: Psychostimulant WithdrawalCrash(Day
Page 85 and 86: Pharmacotherapies for Psychostimula
Page 87 and 88: Initiating MA Abstinence‣ Key Cli
Page 89 and 90: Treatment Resources‣ Methamphetmi

Methamphetamine - UCLA Integrated Substance Abuse Programs

Create successful ePaper yourself

Delete template?

Save as template?